Vistagen says depression treatment failed to meet main goal of mid-stage study

Vistagen reports topline phase 2 results for av-101 as an adjunctive treatment of major depressive disorder.vistagen therapeutics inc - av-101 treatment arm did not differentiate from placebo on primary endpoint.vistagen therapeutics inc - av-101 was well tolerated, with no psychotomimetic side effects or serious adverse events.vistagen therapeutics inc - continue to examine full dataset from study to evaluate effects on other endpoints & pharmacokinetics.vistagen therapeutics inc - possible that efficacy may have been compromised on av-101 trial.vistagen therapeutics inc - during 2020, will review total body of preclinical and clinical work on av-101, across all indications.vistagen therapeutics inc - possible efficacy may have been compromised by insufficient transport of av-101 across blood brain barrier.vistagen therapeutics - possible efficacy may have been compromised by inadequate concentrations of 7-cl-kyna, in brain.
VTGN Ratings Summary
VTGN Quant Ranking